Responses
Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.